Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|January 20, 2026
Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven DiseasesChiara Zecchin, Stein Schalkwijk, Isabelle J Pouliquen, et al.Clinical Pharmacology in Drug Development|July 19, 2019
The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized TrialShaila Shabbir, Isabelle J Pouliquen, Jane H Bentley, et al.European Journal of Pharmacology|January 2, 2013
Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studiesRuth Tal-Singer, Anthony Cahn, Rashmi Mehta, et al.Ophthalmic Surgery and Lasers|May 26, 1998
A prospective randomized trial of topical soluble 0.1% indomethacin versus 0.1% diclofenac versus placebo for the control of pain following excimer laser photorefractive keratectomyM Assouline, G Renard, J L Arne, et al.British Journal of Clinical Pharmacology|September 19, 2002
Quinidine does not affect the renal clearance of moxonidineStephen D Wise, Clark Chan, Hans G Schaefer, et al.Clinical Drug Investigation|June 21, 2013
Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studiesAnthony Cahn, Ruth Tal-Singer, Isabelle J Pouliquen, et al.Journal of Clinical Pharmacology|February 16, 2026
Development of Pediatric Dosing for Mepolizumab in Severe Asthma Based on Extrapolation of Data From Adult Patients and a Phase II Open-Label Pediatric TrialAtul Gupta, Isabelle J Pouliquen, Wanda Phipatanakul, et al.British Journal of Clinical Pharmacology|July 22, 2021
A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthmaDave Singh, Rainard Fuhr, Nicholas P Bird, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 14, 2003
Metabolism and disposition of the antihypertensive agent moxonidine in humansMinxia M He, Trent L Abraham, Thomas J Lindsay, et al.Brain Communications|September 12, 2025
Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50Craig Shering, Michael Pomfret, Robert J Kubiak, et al.Pageof 3